Literature DB >> 27189309

The Pulmonary Hypertension Consult: Clinical and Coding Considerations.

Jason S Fritz1, K Akaya Smith2.   

Abstract

Pulmonary hypertension (PH) is an increasingly recognized cause of morbidity and mortality, and in the past 20 years, there has been a rapid expansion in research and available therapies. Although it is defined quite simply as a mean pulmonary arterial pressure of ≥ 25 mm Hg, PH encompasses a heterogeneous group of disease processes. In the past, PH was classified as primary or secondary, but as understanding of the various contributing diseases has increased, classification systems have attempted to group these diseases by clinical features and disease mechanism. The evaluation of patients with suspected PH can be cumbersome, and a careful and methodical approach is needed to ensure timely and accurate diagnosis, correct physiological classification, and appropriate treatment. In this review, we discuss the classification and diagnostic evaluation of PH in adults as well as some of the billing and coding considerations involved in this evaluation.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypertension; pulmonary; pulmonary circulation

Mesh:

Year:  2016        PMID: 27189309     DOI: 10.1016/j.chest.2016.05.010

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Response.

Authors:  Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Chest       Date:  2019-05       Impact factor: 9.410

2.  Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension.

Authors:  Morgan E Whitaker; Vineet Nair; Shripad Sinari; Parinita A Dherange; Balaji Natarajan; Lindsey Trutter; Evan L Brittain; Anna R Hemnes; Eric D Austin; Kumar Patel; Stephen M Black; Joe G N Garcia; Jason X Yuan Md PhD; Rebecca R Vanderpool; Franz Rischard; Ayako Makino; Edward J Bedrick; Ankit A Desai
Journal:  Am J Med       Date:  2018-02-05       Impact factor: 4.965

Review 3.  The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.

Authors:  Yasunobu Hayabuchi
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

4.  Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007-2013).

Authors:  Lisa A Murphy; Nicholas Russell; Domenico Bianco; Reid K Nakamura
Journal:  Vet Med Sci       Date:  2017-03-08

5.  Lung function in relation to six-minute walk test in pulmonary hypertension.

Authors:  Amir Farkhooy; Michaela Bellocchia; Hans Hedenström; Daniela Libertucci; Caterina Bucca; Christer Janson; Paolo Solidoro; Andrei Malinovschi
Journal:  Eur Clin Respir J       Date:  2020-04-07

6.  Validation of claims-based algorithms for pulmonary arterial hypertension.

Authors:  Ravikanth Papani; Gulshan Sharma; Amitesh Agarwal; Sean J Callahan; Winston J Chan; Yong-Fang Kuo; Yun M Shim; Andrew D Mihalek; Alexander G Duarte
Journal:  Pulm Circ       Date:  2018 Apr-Jun       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.